Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report released on Thursday. The firm issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 0.8 %

Shares of AXDX opened at $1.19 on Thursday. The firm has a market cap of $29.80 million, a PE ratio of -0.42 and a beta of 0.56. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $4.68. The firm has a fifty day simple moving average of $1.70 and a two-hundred day simple moving average of $1.55.

Insider Activity

In related news, Director John Patience acquired 200,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $1.57 per share, with a total value of $314,000.00. Following the transaction, the director now directly owns 653,224 shares in the company, valued at approximately $1,025,561.68. This represents a 44.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 43.60% of the company’s stock.

Hedge Funds Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.